XML 28 R13.htm IDEA: XBRL DOCUMENT
v3.22.4

Revenue | 12 Months Ended
--- | ---
Dec. 31, 2022
Revenue from Contract with Customer [Abstract] |
Revenue | Revenue Our disaggregated revenues were as follows (in thousands):
|  | Year Ended December 31,
|  | 2022 |  | 2021 |  | 2020
Royalties |  | $ | 360,475 |  |  | $ | 203,900 |  |  | $ | 88,596 |
Product sales, net |  |  |  |  |  |
Sales of bulk rHuPH20 |  | 82,084 |  |  | 80,960 |  |  | 38,956 |
Sale of proprietary products |  | 72,849 |  |  | 23,264 |  |  | 17,031 |
Sale of Device Partnered Products |  | 36,097 |  |  | — |  |  | — |
Total product sales, net |  | $ | 191,030 |  |  | $ | 104,224 |  |  | $ | 55,987 |
Revenues under collaborative agreements: |  |  |  |  |  |
Upfront license and target nomination fees |  | 30,000 |  |  | 42,000 |  |  | 37,264 |
Event-based development milestones and regulatory milestone and other fees |  | 59,000 |  |  | 42,000 |  |  | 69,500 |
Sales-based milestones |  | 10,000 |  |  | 50,000 |  |  | 15,000 |
Device Licensing and development revenue |  | 9,611 |  |  | 1,186 |  |  | 1,247 |
Total revenues under collaborative agreements |  | $ | 108,611 |  |  | $ | 135,186 |  |  | $ | 123,011 |
Total revenue |  | $ | 660,116 |  |  | $ | 443,310 |  |  | $ | 267,594 |
During the year ended December 31, 2022 we recognized revenue related to licenses granted to collaboration partners in prior periods in the amount of $429.5 million. This amount represents royalties and sales milestone earned in the current period, as well as $59.0 million of variable consideration in the contracts where uncertainties have been resolved and the development milestones are probable of being achieved or were achieved. We also recognized revenue of $2.0 million during the year ended December 31, 2022 that had been included in deferred revenues at December 31, 2021. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods. Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):
|  | December 31, 2022 |  | December 31, 2021
Accounts receivable, net |  | $ | 186,970 |  |  | $ | 90,975 |
Other contract assets |  | $ | 44,102 |  |  | $ | — |
Deferred revenues |  | $ | 5,499 |  |  | $ | 4,276 |
As of December 31, 2022, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $80.7 million of which $75.2 million relates to unfulfilled product purchase orders and $5.5 million has been collected and reported as deferred revenues. The unfulfilled product purchase orders are estimated to be delivered in 2023. Of the total deferred revenues of $5.5 million, $3.2 million is expected to be used by our customers within the next 12 months. We recognized contract assets of $44.1 million as of December 31, 2022, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.

X
- Definition The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -URI http://asc.fasb.org/topic&trid=5833765 + Details
Name: | us-gaap_CollaborativeArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration